drugset / Trial / NCT05766839

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839

Phase 2 Recruiting 32 enrolled Vifor Pharma
NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.

Timeline

Start
2025-04-06
Primary completion
2029-12-01
Completion
2030-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Patiromer Other / unclassified

Indications

No indication recorded.